PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Tuesday, January 15, 2019.

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a

Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects "The critical role of NK cells and NK-DC crosstalk is part of the broad-based immunologic profile associated with Advaxis Lm vectors and

ts Phase 3 AIM2CERV Study Anticipates Data on ADXS-PSA, ADXS-NEO and ADXS-HOT (NSCLC) in 2019 Conference Call Today at 11:00 a.m. Eastern Time "We believe this approach affords the best opportunity to demonstrate the therapeutic potential of drug candidates generated from our unique and proprietary

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a

Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds PRINCETON, N.J.--( BUSINESS WIRE )--  Advaxis, Inc.  (NASDAQ: ADXS) (“Advaxis” or the “Company”) announced today the closing of its previously announced

  "We are encouraged by the momentum achieved with both of our neoantigen-focused programs during our third fiscal quarter and continue on our path of achieving our goal of having five neoantigen-based product candidates in clinical evaluation by the end of 2019" PRINCETON, N.J.--( BUSINESS WIRE

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS) (“Advaxis” or the “Company”) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq:ADXS) (“Advaxis” or the “Company”) announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to